ArticleBioMedicine2026
Impacts of DNA ligase I genotypes on Taiwan Parkinson's disease.
Article in BioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Genetic polymorphisms in DNA repair pathways can modulate DNA repair capacity and influence susceptibility to aging-related disorders, including Parkinson's disease (PD). This study evaluated the association between the DNA ligase I rs20579 polymorphism and PD risk. Materials and methods: Genotyping of DNA ligase I rs20579 was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 123 PD patients and 492 age- and sex-matched controls of Taiwanese Han ethnicity. Associations between rs20579 genotypes and PD risk were analyzed. Results: Among controls, the genotype distribution of rs20579 was 78.7 % GG, 19.3 % AG, and 2.0 % AA, compared with 75.6 %, 21.1 %, and 3.3 % among PD cases, respectively (p for trend = 0.6290). No significant differences were observed in the prevalence of AG (p = 0.6939) or AA (p = 0.4908) genotypes between cases and controls. Allelic analysis showed a non-significant increase in PD risk for A allele carriers (OR = 1.21, 95 % CI = 0.80-1.83, p = 0.4189). Stratified analysis revealed no significant genotype differences among males. In females, the AA genotype was associated with a borderline increased risk of PD (OR = 1.86, 95 % CI = 1.00-3.47, p = 0.0526). Conclusion: In this Taiwanese Han cohort, the DNA ligase I rs20579 A allele may be a genetic marker of increased PD susceptibility in females. Further studies in larger, independent populations are warranted to confirm its clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.